Skip to content

S. 1040 · 119th Congress (2025–2027)

Drug Competition Enhancement Act

This bill prohibits product hopping by drug manufacturers and authorizes the Federal Trade Commission (FTC) to enforce this prohibition.

Generally, product hopping describes a situation where, when the patents on a reference drug (or biological product) expire, the manufacturer switches to a follow-on product that is covered by a later-expiring patent. Under this bill, a follow-on product is a modified version of the reference drug that has an indication (what the drug is used for) that is identical or substantively similar to an indication of the reference drug.

The bill establishes a presumption that product hopping has occurred when a reference drug manufacturer, after receiving notice that the Food and Drug Administration has received an application to market a competing generic (or biosimilar) version, takes certain actions such as withdrawing the reference drug from the market and selling a follow-on product.

A drug manufacturer may rebut these presumptions by demonstrating that its conduct was not intended to limit competition.

The bill makes product hopping an unfair method of competition and provides for enforcement by the FTC. If the FTC has reason to believe a manufacturer has violated or is about to violate this prohibition on product hopping, the FTC may institute an administrative proceeding or bring suit in federal court to stop the manufacturer’s action and seek equitable remedies, including disgorgement of unjust profits or paying restitution to those harmed.

Show official title

A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes.

Reported

This bill’s path

This is S. 1040’s recorded path, not a universal congressional workflow.

How bills become lawAll actions
  1. Introduced

  2. Passed Senate

  3. Passed House

  4. Sent to President

  5. Signed into law

Sponsor
Sen. John Cornyn (R-TX)
Cosponsors
3 cosponsors

3 original · 0 later

  1. Sen. Richard Blumenthal (D-CT)· Original · Mar 13, 2025
  2. Sen. Richard J. Durbin (D-IL)· Original · Mar 13, 2025
  3. Sen. Chuck Grassley (R-IA)· Original · Mar 13, 2025
Policy area
Health
Subjects
  • Administrative remedies
  • Civil actions and liability
  • Competition and antitrust
  • Consumer affairs
  • Drug safety, medical device, and laboratory regulation
  • Federal Trade Commission (FTC)
  • Health care costs and insurance
  • Inflation and prices
  • 4 more
    • Intellectual property
    • Judicial review and appeals
    • Manufacturing
    • Prescription drugs

On this page

Timeline

i

In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.

  1. Introduced in Senate

    Document: Introduced in Senate

    Sources
  2. Latest
    ▸ 3 committee actions · Mar 13, 2025 – Apr 10, 2025
    1. Referred to committee

      Read twice and referred to the Committee on the Judiciary.

      Sources
    2. Ordered reported

      Committee on the Judiciary. Ordered to be reported with an amendment favorably.

      Sources
    3. Reported by committee

      Committee on the Judiciary. Reported by Senator Grassley with an amendment. Without written report.

      Sources

Committees

  1. SenateJudiciaryReferred Mar 13, 2025 · Markup Apr 3, 2025 · Reported Apr 10, 2025
    1. Apr 3, 2025 · Meeting

Text & titles

i

Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.

Text versions
VersionDateLinks
Introduced in Senate
Reported to Senate
Titles (2)
  1. Drug Competition Enhancement Act

    Short title, Display title · Reported to Senate, Introduced in Senate

  2. A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes.

    Official title · Introduced in Senate